<DOC>
	<DOC>NCT02839746</DOC>
	<brief_summary>Describe patient and physician assessed factors for patient well-being when treated with Pradaxa for stroke and embolism prevention in atrial fibrillation either compared to previous antithrombotic treatment (switcher)</brief_summary>
	<brief_title>Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criteria: Written informed consent prior to participation Female and male patients 18 years of age or older with a diagnosis of nonvalvular atrial fibrillation. At least 6 months of continuous vitamin K antagonist (VKA) treatment for stroke prevention prior to baseline assessment. Patients switched to Pradaxa® according to Summary of Product Characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community. Exclusion criteria: Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC) Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in nonvalvular atrial fibrillation. Current participation in any clinical trial of a drug or device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>